Rhinocort Aqua Use In Pregnancy & Lactation

There are no adequate well-controlled clinical studies in pregnant or breastfeeding women.
Pregnancy: It is not known if budesonide can cross the placenta but due to its relatively low molecular weight, placental transfer may be possible. When given at therapeutic doses, systemic exposure after intranasal administration is low.
Lactation: Budesonide is excreted in breast milk. However, due to negligible systemic exposure, minimal exposure to nasal budesonide in breast-fed infants is expected. The infant daily dose of inhaled budesonide is around 0.3% of the maternal daily dose. There is a linear relationship between budesonide concentration in plasma and breast milk, where concentration of budesonide in breast milk is less than plasma concentration.
Fertility: There are insufficient data available to determine whether intranasal administration of budesonide has the potential to impair fertility.
This product should not be used during pregnancy or lactation unless the potential benefit of treatment to the mother outweighs the possible risks to the developing fetus or breastfeeding infant. Ask a physician before use if the patient is pregnant or breastfeeding.